119th Congress · introduced in the House · May 29, 2026
PREEMPT Act
Official title from Congress.gov
Latest action (May 29, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
7 citations.
THERMO FISHER SCIENTIFIC INC · lobbying firm or registrant: BLUEBIRD STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 16, 2026 · issue area: Health Issues
$21,000
Paid to lobbying firm
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THERMO FISHER SCIENTIFIC INC · lobbying firm or registrant: THERMO FISHER SCIENTIFIC INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 15, 2026 · issue area: Health Issues
$550,000
Spent on own lobbying
…SULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act - all provisions of the bill.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS · lobbying firm or registrant: AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$96,000
Spent on own lobbying
…H.R.8159, Gynecologic Pain Management Study Act; H.R.8160, Premenstrual Dysphoric Disorder Awareness and Research Act; H.R. 9441, SAFE Training for OBGYNs Act; H.R. 9061, PREEMPT Act; H.Res. 1282, a resolution recognizing ACOGs 75th anniversary; H.R. 8358, Breast Cancer Research Stamp Reauthorization Act; S. Res. 710, a resolut…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
MARCH OF DIMES · lobbying firm or registrant: MARCH OF DIMES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Health Issues
$60,000
Spent on own lobbying
…on Act (H.R.3302, S.3799), Momnibus Act (H.R. 7973), Dads Matter Act (H.R. 5828, S. 2131), Rural Obstetrics Readiness Act (H.R. 1254, S. 380), and PREEMPT Act (H.R. 9061), legislation focused on coverage guidance on tests for the screening and early detection of preeclampsia.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
LABORATORY CORPORATION OF AMERICA HOLDINGS · lobbying firm or registrant: LABORATORY CORPORATION OF AMERICA HOLDINGS
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 14, 2026 · issue area: Health Issues
$270,000
Spent on own lobbying
…sions; H.R. 8890, the Enhancing Clinical Laboratory Innovation and Access (Enhancing CLIA) Act, provisions relating to oversight of laboratory-developed tests; H.R. 9061, the Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act, provisions relating to Medicaid coverage of preecla…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THERMO FISHER SCIENTIFIC INC · lobbying firm or registrant: THERMO FISHER SCIENTIFIC INC.
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 13, 2026 · issue area: Health Issues
$280,000
Spent on own lobbying
…SULTS) Act of 2025 - all provisions of the bill. H.R. 5343/S. 1717: Ensuring Patient Access to Critical Breakthrough Products Act - all provisions of the bill. H.R. 9061: Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing (PREEMPT) Act - all provisions of the bill.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
THERMO FISHER SCIENTIFIC INC · lobbying firm or registrant: BLUEBIRD STRATEGIES
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 6, 2026 · issue area: Health Issues
$21,000
Paid to lobbying firm
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing